TP53 and colon carcinoma: Some in vitro studies on human colon carcinoma, immortalised Li–Fraumeni syndrome and promyelocytic leukaemia found that the cell lines with mutant TP53 have lower sensitivity to Ph-PDT than those with wild-type TP53.